Mylan

Silverlight Digital Recognized by MM&M as a Top Healthcare Agency Two Years in a Row

Retrieved on: 
목요일, 7월 12, 2018
Software, Microsoft Silverlight, Mylan, Pharma, System software, Computing

Silverlight Digital's notable work includes a successful campaign with Mylan's allergy medication Dymista and enhanced partnerships with leading healthcare marketing agencies.

Key Points: 
  • Silverlight Digital's notable work includes a successful campaign with Mylan's allergy medication Dymista and enhanced partnerships with leading healthcare marketing agencies.
  • Working directly with brands and their agency counterparts, Silverlight Digital is often called upon to be the creative agency's media agency.
  • "What excites the team at Silverlight Digital is the disruption and change that is occurring across healthcare and pharma advertising," commented Silverlight Digital CEO and Founder Lori Goldberg.
  • Silverlight Digital is a New York-based media agency that adopts a consultative approach to helping healthcare and pharmaceutical brands reach their desired audience.

Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon® Patch

Retrieved on: 
월요일, 7월 9, 2018
Mylan, Rivastigmine, Biotechnology, MYL, Generic drug, Health, Business

HERTFORDSHIRE, England and PITTSBURGH, July 9, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis' Exelon Patch.

Key Points: 
  • HERTFORDSHIRE, England and PITTSBURGH, July 9, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis' Exelon Patch.
  • Mylan President Rajiv Malik said, "The launch of generic Exelon Patch is another example of the investment Mylan is continuing to make into products that are difficult to develop and manufacture, particularly in transdermal drug-delivery systems.
  • The launch of this product also strengthens the company's growing central nervous system portfolio, which is a therapeutic area of continued focus for Mylan as we strive to provide better health for a better world."
  • Currently, Mylan has 196 ANDAs pending FDA approval representing approximately $88.2 billion in annual brand sales, according to IQVIA.

Mylan Launches Generic Angiomax® Injection

Retrieved on: 
월요일, 6월 18, 2018
Mylan, Bivalirudin, Food and Drug Administration, Health, Biotechnology

HERTFORDSHIRE, England and PITTSBURGH, June 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Bivalirudin for Injection, 250 mg single-dose vial, a generic version of Angiomax from The Medicines Company.

Key Points: 
  • HERTFORDSHIRE, England and PITTSBURGH, June 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Bivalirudin for Injection, 250 mg single-dose vial, a generic version of Angiomax from The Medicines Company.
  • Mylan is offering Bivalirudin for Injection, 250 mg single-dose vial, to its hospital and institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA).
  • Bivalirudin for Injection, 250 mg single-dose vial, had U.S. sales of approximately $106 million for the 12 months ending March 31, 2018, according to IQVIA.
  • Currently, Mylan has 199 ANDAs pending FDA approval representing approximately $88.5 billion in annual brand sales, according to IQVIA.

Americares Honors Mylan with Power of Partnership Award

Retrieved on: 
월요일, 6월 11, 2018
AmeriCares, Mylan, HDA, Health in the United States, United States, Connecticut

STAMFORD, Conn., June 11, 2018 /PRNewswire/ --Americares, in partnership with the Healthcare Distribution Alliance (HDA), has presented its annual Power of Partnership Award to Mylan, in recognition of its outstanding commitment to increasing access to health care around the world.

Key Points: 
  • STAMFORD, Conn., June 11, 2018 /PRNewswire/ --Americares, in partnership with the Healthcare Distribution Alliance (HDA), has presented its annual Power of Partnership Award to Mylan, in recognition of its outstanding commitment to increasing access to health care around the world.
  • Americares and HDA created the Power of Partnership Award in 2005 to recognize HDA-member pharmaceutical manufacturing and distribution organizations that have shown exceptional dedication to expanding access to health care for disadvantaged populations.
  • Mylan has supported Americares for nearly 30 years, providing more than $670 million worth of medicine for patients in need.
  • We are humbled and honored to receive this year's Power of Partnership Award and look forward to partnering with Americares for decades to come."

U.S. FDA Approves Mylan and Biocon's Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®

Retrieved on: 
월요일, 6월 4, 2018
Biotechnology, Medicine, Biology, Recombinant proteins, RTT, Biocon, Companies based in Bangalore, Biosimilar, Pegfilgrastim, Mylan, Food and Drug Administration, Insulin

Fulphila is the first FDA-approved biosimilar to Neulasta and the second biosimilar from Mylan and Biocon's joint portfolio approved in the U.S. Mylan anticipates launching Fulphila in the coming weeks, representing the first alternative, more affordable treatment option to Neulasta for oncology patients.

Key Points: 
  • Fulphila is the first FDA-approved biosimilar to Neulasta and the second biosimilar from Mylan and Biocon's joint portfolio approved in the U.S. Mylan anticipates launching Fulphila in the coming weeks, representing the first alternative, more affordable treatment option to Neulasta for oncology patients.
  • Mylan President Rajiv Malik added: "Today's approval of Fulphila represents a meaningful step forward in the affordability and accessibility of cancer care in the U.S.
  • The data demonstrated that there were no clinically meaningful differences between the biosimilar product and Neulasta in terms of safety, purity and potency.
  • Our biosimilar to Neulasta is one of 11 biologic and insulin products co-developed by Mylan and Biocon for the global marketplace.

Mylan to Present at Goldman Sachs 39th Annual Global Healthcare Conference

Retrieved on: 
금요일, 6월 1, 2018
Geography of California, South Bay, Los Angeles, Geography of Southern California, Heather Bresch, Mylan, Bresch, MYL, Palos Verdes Peninsula, Rancho Palos Verdes, California

HERTFORDSHIRE, England and PITTSBURGH, June 1, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that CEO Heather Bresch will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA, on Wednesday, June 13, 2018, at 1:20 p.m. PT / 4:20 p.m.

Key Points: 
  • HERTFORDSHIRE, England and PITTSBURGH, June 1, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that CEO Heather Bresch will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA, on Wednesday, June 13, 2018, at 1:20 p.m. PT / 4:20 p.m.
  • Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's website at investor.mylan.com .
  • An archived version also will be available following the live presentation and can be accessed at the same location for a limited time.
  • Mylan is a global pharmaceutical company committed to setting new standards in healthcare.

33 Top US Companies Short-Listed in 10 categories for USA-Europe Shared Services Awards, June 20th, New York

Retrieved on: 
목요일, 5월 31, 2018
Economy of the United States, Finance, Economy of New York City, Groupon, Mylan, NASDAQ, Morgan Stanley, Estee, Cisco Systems

We have nearly 30 VIP Jury members, many of whom are US-based companies who have direct oversight of SSCs in Europe/CEE, or global process directors.

Key Points: 
  • We have nearly 30 VIP Jury members, many of whom are US-based companies who have direct oversight of SSCs in Europe/CEE, or global process directors.
  • Jury Members include US-based Global Directors with operations in Eastern Central Europe, including: Groupon, StateStreet, Cisco, Citi, NASDAQ, Johnson&Johnson, BrownBrothersHarriman, MorganStanley, Mylan, Groupon, Flowserve, BectonDickinson (BD), Estee Lauder, etc.
  • : http://www.sharedserviceseurope.com/vip-jury.html
    We expect a total of about 150 focused top execs at the Awards Gala, including about 40 top SSC/GBS execs who oversee delivery centres in more than 9 countries in Europe.
  • The full-day Summit includes more than 15 Panelists: http://www.sharedserviceseurope.com/agenda2.html
    Photos from last year's event: http://www.sharedserviceseurope.com/photos-2017.html
    Location: Members-only New York Athletic Club, 180 Central Park South, New York.

Mylan to Release First Quarter 2018 Financial Results on May 9, 2018

Retrieved on: 
수요일, 5월 2, 2018
Mylan, MYL, NASDAQ, Economy of the United States, Economy, New York City

HERTFORDSHIRE, England and PITTSBURGH, May 2, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its first quarter 2018 financial results, on Wed., May 9, before the open of the U.S. financial markets.

Key Points: 
  • HERTFORDSHIRE, England and PITTSBURGH, May 2, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its first quarter 2018 financial results, on Wed., May 9, before the open of the U.S. financial markets.
  • ET on May 9, to discuss the results.
  • The briefing can be accessed live by calling800.514.4861 or678.809.2405for international callers (ID#: 2194037) or at the following address on the company's website: investor.mylan.com.
  • Mylan is a global pharmaceutical company committed to setting new standards in healthcare.

Mylan Adds to Growing Women's Healthcare Portfolio with Launch of Generic for Oral Contraceptive Yaz®

Retrieved on: 
수요일, 4월 25, 2018
Health, Mylan, Biotechnology, Food and Drug Administration, Pharmaceutical industry, IQVIA, Epinephrine autoinjector, Heather Bresch

In the U.S., Mylan offers more than 20 generic birth control medicines in multiple dosage forms.

Key Points: 
  • In the U.S., Mylan offers more than 20 generic birth control medicines in multiple dosage forms.
  • The products are a part of Mylan's growing U.S. women's healthcare portfolio, which includes a vast suite of medicines to help women manage their health across all the stages of their lives.
  • In all, Mylan currently has 204 ANDAs pending FDA approval representing approximately $90.8 billion in annual brand sales, according to IQVIA.
  • Mylan is a global pharmaceutical company committed to setting new standards in healthcare.

Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting

Retrieved on: 
토요일, 4월 21, 2018
Mylan, Glatiramer acetate, American Academy of Neurology, Medicine, MYL, Aan, Health care, Clinical medicine

HERTFORDSHIRE, England, and PITTSBURGH, April 21, 2018 /PRNewswire/ --Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced three scientific abstracts from the Glatiramer Acetate development program will be presented at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, April 21-27.

Key Points: 
  • HERTFORDSHIRE, England, and PITTSBURGH, April 21, 2018 /PRNewswire/ --Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced three scientific abstracts from the Glatiramer Acetate development program will be presented at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, April 21-27.
  • Mylan's Head of Morgantown Research & Development Patrick Vallano commented, "We are excited to present at this year's American Academy of Neurology annual meeting Mylan's rigorous equivalence data that demonstrated sameness between Mylan's Glatiramer Acetate and Copaxone.
  • We believe a world-renowned venue like AAN's annual meeting is the perfect opportunity for Mylan to showcase and discuss the strong science behind our Glatiramer Acetate."
  • Mylan's data will be presented during the following poster sessions at the meeting and later available in "Neurology," the official journal of AAN.